← Back
$MYNZ All transactions

MAINZ BIOMED N.V.

A

$ Value

Shares

1,000,000

Price

Filed

Mar 3

Insider

Name

Lazar David E.

Title

CIK

0001932843

Roles

Director

Transaction Details

Transaction Date

2026-02-13

Code

A

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

1,000,000

Footnotes

No ordinary shares are beneficially owned. | On February 13, 2026 David E. Lazar (the "Reporting Person") and Mainz Biomed N.V. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares"), at a price of $1.00 per share, for a total purchase price of $3,000,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing promptly following effectiveness of the Stockholder Approval (as defined below), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and, together with the First Closing Shares, the "Preferred Shares"), at a price of $1.50 per share, for an additional purchase price of $3,000,000. | The First Closing Shares are not convertible into ordinary shares until Stockholder Approval is obtained. Following Stockholder Approval, each of the First Closing Shares will be convertible into 9 ordinary shares and each of the Second Closing Shares will be convertible into 225 ordinary shares, subject to certain ownership limitations. No Preferred Shares will be convertible until the Company's stockholders approve (a) an increase in the Company's authorized ordinary shares to at least 900,000,000, (b) the conversion of all Preferred Shares into ordinary shares in compliance with the rules and regulations of the Nasdaq Capital Market, (c) a reverse stock split, and (d) the election of the Reporting Person and his designees to the Company's Board of Directors (collectively, the "Stockholder Approval"). | Following receipt by the Company of the Stockholder Approval, the Preferred Stock will be convertible into ordinary shares at the option of the Reporting Person for no additional consideration. | Each class of Preferred Stock is perpetual and therefore has no expiration date.

Filing Info

Accession No.

0000921895-26-000581

Form Type

4

Issuer CIK

0001874252

Lazar David E.'s History

Date Ticker Type Value
2026-03-31 SOWG A $820K
2026-03-23 INDP
2026-03-23 INDP
2026-02-13 MYNZ A
2026-02-13 MYNZ A
2026-02-13 MYNZ A
2025-12-31 SOWG M $820K
2025-12-31 SOWG A $3.0M
2025-12-18 KALA J
2025-11-24 KALA A

Other Insiders at MYNZ (90d)

Insider Bought Sold Last
Tibbitts Gregory J 2026-02-13
Dreismann Heinrich 2026-02-13
Caragol William J
Chief Financial Officer
2026-02-13
BAECHLER GUIDO
Chief Executive Officer
2026-02-13
Lazar David E. 2026-02-13